Research Article
A Predictive Model for Nonsentinel Node Status after Sentinel Lymph Node Biopsy in Sentinel Lymph Node-Positive Chinese Women with Early Breast Cancer
Table 2
Univariate analysis of non-SLN status in 228 SLN-positive patients with early breast cancer.
| | Data | Non-SLN metastasis; absent; n = 116 (50.9%) | Non-SLN metastasis; present; n = 112 (49.1%) | Total n = 228 | value |
| | Age | | ≤35 | 12 (10.3%) | 4 (3.6%) | 16 | 0.045 | | >35 | 104 (89.6%) | 108 (96.4%) | 212 | | Menopausal status | | Premenopausal | 57 (49.1%) | 59 (52.7%) | 116 | 0.593 | | Postmenopausal | 59 (50.9%) | 53 (47.3%) | 112 | | Tumor location | | Upper outer | 57 (49.6%) | 59 (52.7%) | 114 | 0.828 | | Lower outer | 15 (13.0%) | 17 (15.2%) | 32 | | Lower inner | 6 (5.2%) | 7 (6.2%) | 13 | | Upper inner | 23 (20.0%) | 20 (17.9%) | 43 | | Central | 14 (12.2%) | 9 (8.0%) | 23 | | Tumor size (cm) | | Mean | 3.03 | 3.59 | 3.31 | 0.828 | | Median | 3.00 | 3.40 | 3.00 | | SD | 1.11 | 1.39 | 1.29 | | Tumor type | | Infiltrating ductal carcinoma | 105 (90.5%) | 97 (86.6%) | 202 | 0.214 | | Invasive lobular carcinoma | 2 (1.7%) | 7 (6.3%) | 9 | | Other carcinomas | 9 (7.8%) | 8 (7.1%) | 17 | | Lymphovascular invasion | | Yes | 8 (6.9%) | 23 (20.5%) | 31 | 0.003 | | No | 108 (93.1%) | 89 (79.5%) | 197 | | Histological grade | | G1 | 7 (6.0%) | 5 (4.5%) | 12 | 0.841 | | G2 | 37 (31.9%) | 32 (28.5%) | 69 | | G3 | 66 (56.9%) | 70 (62.5%) | 136 | | Gx | 6 (5.2%) | 5 (4.5%) | 11 | | Multifocality | | Yes | 4 (3.4%) | 14 (12.5%) | 18 | 0.011 | | No | 112 (96.6%) | 98 (87.5%) | 210 | | Estrogen receptor | | Negative | 34 (29.3%) | 25 (22.3%) | 59 | 0.228 | | Positive | 82 (70.7%) | 87 (77.7%) | 169 | | Progesterone receptor | | Negative | 44 (37.9%) | 43 (38.4%) | 87 | 0.943 | | Positive | 72 (62.1%) | 69 (61.6%) | 141 | | HER2/neu receptor | | Negative | 82 (70.7%) | 83 (74.1%) | 165 | 0.564 | | Positive | 34 (29.3%) | 29 (25.9%) | 63 | | Ki-67 status | | ≤14% | 19 (16.4%) | 14 (12.5%) | 33 | 0.405 | | >14% | 97 (83.6%) | 98 (87.5%) | 195 | | Molecular subtypes | | Luminal A | 16 (13.8%) | 12 (10.7%) | 28 | 0.415 | | Luminal B1 | 51 (44.0%) | 62 (55.4%) | 113 | | Luminal B2 | 17 (14.7%) | 12 (10.7%) | 29 | | Her2-positive | 17 (14.7%) | 17 (15.2%) | 34 | | Triple negativity | 15 (12.9%) | 9 (8.0%) | 24 | | Number of SLN | | Mean | 2.96 | 2.84 | 2.9 | 0.558 | | Median | 3.0 | 3.0 | 3.0 | | SD | 1.53 | 1.43 | 1.48 | | Number of metastatic SLN | | Mean | 1.31 | 1.56 | 1.43 | 0.009 | | Median | 1 | 1 | 1 | | SD | 0.58 | 0.84 | 0.73 | | Number of nonmetastatic SLN | | Mean | 1.65 | 1.28 | 1.46 | 0.034 | | Median | 1 | 1 | 1 | | SD | 1.41 | 1.26 | 1.35 |
|
|
